![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB |
![[thumbnail of Supplementary Information]](https://edoc.mdc-berlin.de/style/images/fileicons/application_msword.png) |
MS Word (Supplementary Information)
5MB |
| Item Type: | Article |
|---|---|
| Title: | Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry |
| Creators Name: | Gampenrieder, S.P., Rinnerthaler, G., Tinchon, C., Petzer, A., Balic, M., Heibl, S., Schmitt, C., Zabernigg, A.F., Egle, D., Sandholzer, M., Singer, C.F., Roitner, F., Hager, C., Andel, J., Hubalek, M., Knauer, M. and Greil, R. |
| Abstract: | BACKGROUND: About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low HER2 expression is a promising new target for antibody-drug conjugates (ADCs) currently under investigation. Until now, little is known about the frequency and the prognostic value of low HER2-expression in metastatic breast cancer (MBC). PATIENTS AND METHODS: The MBC-Registry of the Austrian Study Group of Medical Tumor Therapy (AGMT) is a multicenter nationwide ongoing registry for MBC patients in Austria. Unadjusted, univariate survival probabilities of progression-free survival (PFS) and overall survival (OS) were calculated by the Kaplan-Meier method and compared by the log-rank test. Multivariable adjusted hazard ratios were estimated by Cox regression models. In this analysis, only patients with known HER2 status and available survival data were included. RESULTS: As of 11/15/2020, 1,973 patients were included in the AGMT-MBC-Registry. Out of 1,729 evaluable patients, 351 (20.3%) were HER2-positive, 608 (35.2%) were HER2-low and 770 (44.5%) were completely HER2-negative (HER2-0). Low HER2-expression was markedly more frequent in the hormone-receptor(HR)+ subgroup compared to the triple-negative subgroup (40% vs. 23%). In multivariable analysis, low HER2 expression did not significantly influence OS neither in the HR+ (HR 0.89; 95% CI 0.74-1.05; P = 0.171) nor in the triple-negative subgroup (HR 0.92; 95% CI 0.68-1.25; P = 0.585), when compared to completely HER2-negative disease. Similar results were observed when HER2 IHC 2+ patients were compared to IHC 1+ or 0 patients. CONCLUSION: Low-HER2 expression did not have any impact on prognosis of metastatic breast cancer in this real-world population. |
| Keywords: | Metastatic Breast Cancer, HER2-Low, HER2-Positive, HER2-Negative, OS, PFS, Registry, Real-World Data |
| Source: | Breast Cancer Research |
| ISSN: | 1465-542X |
| Publisher: | BioMed Central |
| Volume: | 23 |
| Number: | 1 |
| Page Range: | 112 |
| Date: | 14 December 2021 |
| Official Publication: | https://doi.org/10.1186/s13058-021-01492-x |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
